Stock BAXALTA INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Baxalta Inc

Equities

US07177M1036

End-of-day quote Nyse
Other stock markets
- USD - Intraday chart for Baxalta Inc
2016 Baxalta : Shire jumps as Vyvanse drug helps it to beat earnings forecast RE
2016 Baxalta : Shire director pay resolution just scrapes though at general meet RE

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Baxalta : Shire Completes Combination With Baxalta Creating the Global Leader in Rare Diseases and Highly Specialized Conditions
PR
Baxalta : CORRECTING and REPLACING Baxalta Shareholders Vote to Approve Combination
BU
Baxalta : OncoResponse Secures Investment from Baxalta
BU
Baxalta : Reports Positive Phase 1 Results for BAX 930, Investigational Recombinant ADAMTS13 to Treat Hereditary Thrombotic Thrombocytopenic Purpura (hTTP)
BU
Baxalta : Thunderbolt Pharma, Inc., a Vitesse Biologics Company, Acquires Rights to BAFF/APRIL Dual Antagonist Program from Astellas Pharma Inc.
BU
Baxalta : Announces Preliminary Merger Consideration Election Results
BU
Baxalta : Merrimack and Baxalta Announce Initiation of Phase 1 Study of MM-151 in Combination with the ONIVYDE® (irinotecan liposome injection) Regimen in Metastatic Colorectal Cancer
PR
Baxalta : Declares Quarterly Dividend
BU
Baxalta : Baxter Increases the Size of Its Previously Announced Offer to Exchange Shares of Baxter for Shares of Baxalta
BU
Baxalta : Receives Positive Opinion from Europe’s CHMP for HYQVIA to Treat Pediatric Patients
BU
Baxalta : Shire jumps as Vyvanse drug helps it to beat earnings forecast
RE
Baxalta : Shire director pay resolution just scrapes though at general meet
RE
Baxalta : Exceeds Guidance and Delivers Strong Sales and Earnings for First Quarter 2016
BU
Baxalta : Baxter Initiates Offer to Exchange Shares of Baxter for Shares of Baxalta
BU
Baxalta : Supports Research to Raise Awareness of Treatment Burden on Patients during the Sixth Annual World Primary Immunodeficiency Week
BU
Baxalta : Announces Date for Special Meeting of Stockholders to Vote on Combination With Shire
BU
Baxalta : Expands Global Reach of ADYNOVATE for Hemophilia A Patients with Approval in Japan
BU
Baxalta : Announces Pricing of Secondary Offering of Common Stock
BU
Baxalta : Announces Secondary Offering of Common Stock
BU
Baxalta : Commences Phase 1 Clinical Trial of BAX 826, the Company’s Second Extended Half-Life Factor VIII Treatment for Hemophilia A
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Baxalta Inc